# US 2003/0083306 A1 · 3'-prodrugs of 2'-deoxy-beta-L-nucleosides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083306 A1
- Document ID: US20030083306A1
- Status: Published application
- Kind: A1
- Application number: 09/883,033
- Filed: 2001-06-15
- Published: 2003-05-01
- Earliest claimed: 2000-06-15
- Assignees: Idenix Pharmaceuticals, Inc.; Cnrs; L'Universite Montpellier II
- Inventors: Jean-Louis Imbach; Martin L. Bryant; Gilles Gosselin
- Web page: https://patentgrep.com/patent/US20030083306A1

## CPC

- C07H 19/16: Purine radicals
- C07H 19/06: Pyrimidine radicals
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3′-esters of 2′-deoxy-β-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents. Compound and compositions of 3′,5′-diesters of 2′-deoxy-β-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents, are also disclosed.

## Claims

### Claim 1

A 3′-substituted-β-L nucleoside of the formula (I):
29
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
X is O, S, SO2 or CH2; and
BASE is a purine or pyrimidine base that may optionally be substituted.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R2 is CO-alkyl.

### Claim 4 (depends on 2)

The compound of claim 2, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 5 (depends on 4)

The compound of claim 4, wherein R2 is L-valinyl.

### Claim 6 (depends on 2)

The compound of claim 2, wherein R1 is hydrogen.

### Claim 7 (depends on 2)

The compound of claim 2, wherein R1 is CO-alkyl.

### Claim 8 (depends on 2)

The compound of claim 2, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 9 (depends on 8)

The compound of claim 8, wherein R1 is L-valinyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 and R2 are independently L-valinyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the 3′-substituted-β-L nucleoside is a β-L-2′-deoxypurine of the formula:
30
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
Y is OR3, NR3R4 or SR3; and
X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, halogen, OR5, NR5R6 or SR5; and
R3, R4, R5 and R6 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene (in particular, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R2 is CO-alkyl.

### Claim 13 (depends on 11)

The compound of claim 11, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 14 (depends on 13)

The compound of claim 13, wherein R2 is L-valinyl.

### Claim 15 (depends on 11)

The compound of claim 11, wherein R1 is hydrogen.

### Claim 16 (depends on 11)

The compound of claim 11, wherein R1 is CO-alkyl.

### Claim 17 (depends on 11)

The compound of claim 11, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 18 (depends on 17)

The compound of claim 17, wherein R1 is L-valinyl.

### Claim 19 (depends on 11)

The compound of claim 11, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 20 (depends on 11)

The compound of claim 11, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 21 (depends on 20)

The compound of claim 20, wherein R1 and R2 are independently L-valinyl.

### Claim 22 (depends on 11)

The compound of claim 11, wherein the β-L-2′-deoxypurine is a β-L-2′-deoxyadenosine of the formula:
31
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R3 and R4 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene (in particular, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R2 is CO-alkyl.

### Claim 24 (depends on 23)

The compound of claim 23, wherein the CO-alkyl is CO-methyl.

### Claim 25 (depends on 23)

The compound of claim 23, wherein the CO-alkyl is CO-propyl.

### Claim 26 (depends on 22)

The compound of claim 22, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 27 (depends on 26)

The compound of claim 26, wherein R2 is L-valinyl.

### Claim 28 (depends on 22)

The compound of claim 22, wherein R1 is hydrogen.

### Claim 29 (depends on 22)

The compound of claim 22, wherein R1 is not hydrogen.

### Claim 30 (depends on 22)

The compound of claim 22, wherein R1 is CO-alkyl.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the CO-alkyl is CO-methyl.

### Claim 32 (depends on 30)

The compound of claim 30, wherein the CO-alkyl is CO-propyl.

### Claim 33 (depends on 22)

The compound of claim 22, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 34 (depends on 33)

The compound of claim 33, wherein R1 is L-valinyl.

### Claim 35 (depends on 22)

The compound of claim 22, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 36 (depends on 22)

The compound of claim 22, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 37 (depends on 22)

The compound of claim 22, wherein R1 and R2 are independently acyl.

### Claim 38 (depends on 22)

The compound of claim 22, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 39 (depends on 38)

The compound of claim 38, wherein R1 and R2 are independently L-valinyl.

### Claim 40 (depends on 38)

The compound of claim 38, wherein R3 and R4 are hydrogen.

### Claim 41 (depends on 38)

The compound of claim 38, wherein R3 is hydrogen and R4 is dimethylamino methylene.

### Claim 42 (depends on 38)

The compound of claim 38, wherein R3 is hydrogen and R4 is CO-alkyl.

### Claim 43 (depends on 38)

The compound of claim 38, wherein R3 is hydrogen and R4 is CO-methyl.

### Claim 44 (depends on 38)

The compound of claim 38, wherein R3 is hydrogen and R4 is L-valinyl.

### Claim 45 (depends on 11)

The compound of claim 11, wherein the β-L-2′-deoxypurine is β-L-2′-deoxy-guanosine of the formula:
32
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R5 and R6 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene (in particular, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 46 (depends on 45)

The compound of claim 45, wherein R2 is CO-alkyl.

### Claim 47 (depends on 46)

The compound of claim 46, wherein the CO-alkyl is CO-methyl.

### Claim 48 (depends on 46)

The compound of claim 46, wherein the CO-alkyl is CO-propyl.

### Claim 49 (depends on 45)

The compound of claim 45, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 50 (depends on 49)

The compound of claim 49, wherein R2 is L-valinyl.

### Claim 51 (depends on 45)

The compound of claim 45, wherein R1 is hydrogen.

### Claim 52 (depends on 45)

The compound of claim 45, wherein R1 is not hydrogen.

### Claim 53 (depends on 45)

The compound of claim 45, wherein R1 is CO-alkyl.

### Claim 54 (depends on 53)

The compound of claim 53, wherein the CO-alkyl is CO-methyl.

### Claim 55 (depends on 53)

The compound of claim 53, wherein the CO-alkyl is CO-propyl.

### Claim 56 (depends on 45)

The compound of claim 45, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 57 (depends on 56)

The compound of claim 56, wherein R1 is L-valinyl.

### Claim 58 (depends on 45)

The compound of claim 45, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 59 (depends on 45)

The compound of claim 45, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 60 (depends on 45)

The compound of claim 45, wherein R1 and R2 are independently acyl.

### Claim 61 (depends on 45)

The compound of claim 45, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 62 (depends on 61)

The compound of claim 61, wherein R1 and R2 are independently L-valinyl.

### Claim 63 (depends on 62)

The compound of claim 62, wherein R5 and R6 are hydrogen.

### Claim 64 (depends on 62)

The compound of claim 62, wherein R5 is hydrogen and R6 is dimethylaminomethylene.

### Claim 65 (depends on 62)

The compound of claim 62, wherein R5 is hydrogen and R6 is CO-alkyl.

### Claim 66 (depends on 62)

The compound of claim 62, wherein R5 is hydrogen and R6 is CO-methyl.

### Claim 67 (depends on 62)

The compound of claim 62, wherein R5 is hydrogen and R6 is L-valinyl.

### Claim 68 (depends on 11)

The of claim 11, wherein the β-L-2′-deoxypurine is β-L-2′-deoxyinosine of the formula:
33
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 69 (depends on 68)

The compound of claim 68, wherein R2 is CO-alkyl.

### Claim 70 (depends on 69)

The compound of claim 69, wherein the CO-alkyl is CO-methyl.

### Claim 71 (depends on 69)

The compound of claim 69, wherein the CO-alkyl is CO-propyl.

### Claim 72 (depends on 68)

The compound of claim 68, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 73 (depends on 72)

The compound of claim 72, wherein R2 is L-valinyl.

### Claim 74 (depends on 68)

The compound of claim 68, wherein R1 is hydrogen.

### Claim 75 (depends on 8)

The compound of claim 8, wherein R1 is not hydrogen.

### Claim 76 (depends on 68)

The compound of claim 68, wherein R1 is CO-alkyl.

### Claim 77 (depends on 76)

The compound of claim 76, wherein the CO-alkyl is CO-methyl.

### Claim 78 (depends on 76)

The compound of claim 76 wherein the CO-alkyl is CO-propyl.

### Claim 79 (depends on 68)

The compound of claim 68, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 80 (depends on 79)

The compound of claim 79, wherein R1 is L-valinyl.

### Claim 81 (depends on 68)

The compound of claim 68, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 82 (depends on 68)

The compound of claim 68 wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 83 (depends on 68)

The compound of claim 68, wherein R1 and R2 are independently acyl.

### Claim 84 (depends on 68)

The compound of claim 68, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 85 (depends on 84)

The compound of claim 84, wherein R1 and R2 are independently L-valinyl.

### Claim 86 (depends on 2)

The compound of claim 2, wherein the 3′-substituted-β-L nucleoside is a β-L-2′-deoxypyrimidine of the formula:
34
or its pharmaceutically acceptable salt therein, wherein
R1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
Y is OR3, NR3R4 or SR3;
X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, halogen, OR5, NR5R6 or SR5; and
R3, R4, R5 and R6 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene (in particular, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 87 (depends on 86)

The compound of claim 86, wherein R2 is CO-alkyl.

### Claim 88 (depends on 86)

The compound of claim 86, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 89 (depends on 88)

The compound of claim 88, wherein R2 is L-valinyl.

### Claim 90 (depends on 86)

The compound of claim 86, wherein R1 is hydrogen.

### Claim 91 (depends on 86)

The compound of claim 86, wherein R1 is CO-alkyl.

### Claim 92 (depends on 86)

The compound of claim 86, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 93 (depends on 92)

The compound of claim 92, wherein R1 is L-valinyl.

### Claim 94 (depends on 86)

The compound of claim 86, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 95 (depends on 86)

The compound of claim 86, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 96 (depends on 95)

The compound of claim 95, wherein R1 and R2 are independently L-valinyl.

### Claim 97 (depends on 86)

The compound of claim 86, wherein the β-L-2′-deoxypyrimidine is a β-L-2′-deoxycytidine of the formula:
35
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R3 and R4 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene (in particular, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 98 (depends on 97)

The compound of claim 97, wherein R2 is CO-alkyl.

### Claim 99 (depends on 98)

The compound of claim 98, wherein the CO-alkyl is CO-methyl.

### Claim 100 (depends on 98)

The compound of claim 98, wherein the CO-alkyl is CO-propyl.

### Claim 101 (depends on 97)

The compound of claim 97, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 102 (depends on 101)

The compound of claim 101, wherein R2 is L-valinyl.

### Claim 103 (depends on 97)

The compound of claim 97, wherein R1 is hydrogen.

### Claim 104 (depends on 97)

The compound of claim 97, wherein R1 is not hydrogen.

### Claim 105 (depends on 97)

The compound of claim 97, wherein R1 is CO-alkyl.

### Claim 106 (depends on 105)

The compound of claim 105, wherein the CO-alkyl is CO-methyl.

### Claim 107 (depends on 105)

The compound of claim 105, wherein the CO-alkyl is CO-propyl.

### Claim 108 (depends on 97)

The compound of claim 97, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 109 (depends on 108)

The compound of claim 108, wherein R1 is L-valinyl.

### Claim 110 (depends on 97)

The compound of claim 97, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 111 (depends on 97)

The compound of claim 97, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 112 (depends on 97)

The compound of claim 97, wherein R1 and R2 are independently acyl.

### Claim 113 (depends on 97)

The compound of claim 97, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 114 (depends on 113)

The compound of claim 113, wherein R1 and R2 are independently L-valinyl.

### Claim 115 (depends on 114)

The compound of claim 114, wherein R3 and R4 are hydrogen.

### Claim 116 (depends on 114)

The compound of claim 114, wherein R3 is hydrogen and R4 is dimethylaminomethylene.

### Claim 117 (depends on 114)

The compound of claim 114, wherein R3 is hydrogen and R4 is CO-alkyl.

### Claim 118 (depends on 117)

The compound of claim 117, wherein R3 is hydrogen and R4 is CO-methyl.

### Claim 119 (depends on 114)

The compound of claim 114, wherein R3 is hydrogen and R4 is L-valinyl.

### Claim 120 (depends on 86)

The compound of claim 86, wherein the β-L-2′-deoxypyrimidine is a β-L-2′-deoxyuridine of the formula:
36
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 121 (depends on 120)

The compound of claim 120, wherein R2 is CO-alkyl.

### Claim 122 (depends on 121)

The compound of claim 121, wherein the CO-alkyl is CO-methyl.

### Claim 123 (depends on 121)

The compound of claim 121, wherein the CO-alkyl is CO-propyl.

### Claim 124 (depends on 120)

The compound of claim 120, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 125 (depends on 124)

The compound of claim 124, wherein R2 is L-valinyl.

### Claim 126 (depends on 120)

The compound of claim 120, wherein R1 is hydrogen.

### Claim 127 (depends on 120)

The compound of claim 120, wherein R1 is not hydrogen.

### Claim 128 (depends on 120)

The compound of claim 120, wherein R1 is CO-alkyl.

### Claim 129 (depends on 128)

The compound of claim 128, wherein the CO-alkyl is CO-methyl.

### Claim 130 (depends on 128)

The compound of claim 128, wherein the CO-alkyl is CO-propyl.

### Claim 131 (depends on 120)

The compound of claim 120, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 132 (depends on 131)

The compound of claim 131, wherein R1 is L-valinyl.

### Claim 133 (depends on 120)

The compound of claim 120, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 134 (depends on 120)

The compound of claim 120, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 135 (depends on 120)

The compound of claim 120, wherein R1 and R2 are independently acyl.

### Claim 136 (depends on 120)

The compound of claim 120, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 137 (depends on 136)

The compound of claim 136, wherein R1 and R2 are independently L-valinyl.

### Claim 138 (depends on 86)

The compound of claim 86, wherein the β-L-2′-deoxypyrimidine is a β-L-thymidine of the formula:
37
or its pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
R2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.

### Claim 139 (depends on 138)

The compound of claim 138, wherein R2 is CO-alkyl.

### Claim 140 (depends on 139)

The compound of claim 139, wherein the CO-alkyl is CO-methyl.

### Claim 141 (depends on 139)

The compound of claim 139, wherein the CO-alkyl is CO-propyl.

### Claim 142 (depends on 138)

The compound of claim 138, wherein R2 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 143 (depends on 142)

The compound of claim 142, wherein R2 is L-valinyl.

### Claim 144 (depends on 138)

The compound of claim 138, wherein R1 is hydrogen.

### Claim 145 (depends on 138)

The compound of claim 138, wherein R1 is not hydrogen.

### Claim 146 (depends on 138)

The compound of claim 138, wherein R1 is CO-alkyl.

### Claim 147 (depends on 146)

The compound of claim 146, wherein the CO-alkyl is CO-methyl.

### Claim 148 (depends on 146)

The compound of claim 146, wherein the CO-alkyl is CO-propyl.

### Claim 149 (depends on 138)

The compound of claim 138, wherein R1 is an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 150 (depends on 149)

The compound of claim 149, wherein R1 is L-valinyl.

### Claim 151 (depends on 138)

The compound of claim 138, wherein R1 is hydrogen and R2 is CO-alkyl.

### Claim 152 (depends on 138)

The compound of claim 138, wherein R1 is hydrogen and R2 is L-valinyl.

### Claim 153 (depends on 138)

The compound of claim 138, wherein R1 and R2 are independently acyl.

### Claim 154 (depends on 138)

The compound of claim 138, wherein R1 and R2 are independently an amino acid residue of the formula C(O)C(R8)(R9)(NR10R11), wherein
R8 is the side chain of an amino acid and wherein, as in proline, R8 can optionally be attached to R10 to form a ring structure; or alternatively, R8 is an alkyl, aryl, heteroaryl or heterocyclic moiety;
R9 is hydrogen, alkyl (including lower alkyl) or aryl; and
R10 and R11 are independently hydrogen, acyl (including an acyl derivative attached to R8) or alkyl (including but not limited to methyl, ethyl, propyl, and cyclopropyl).

### Claim 155 (depends on 154)

The compound of claim 154, wherein R1 and R2 are independently L-valinyl.

### Claim 156

A compound of the formula
38
or its pharmaceutically acceptable salt thereof.

### Claim 157

A compound of the formula
39
or its pharmaceutically acceptable salt thereof.

### Claim 158 (depends on 1)

A pharmaceutical composition for the treatment or prophylaxis of a hepatitis B virus infection in a host comprising the compound of claim 1, or its pharmaceutically acceptable salt, together with a pharmaceutically acceptable carrier or diluent.

### Claim 159 (depends on 1)

A pharmaceutical composition for the treatment or prophylaxis of a hepatitis B virus infection in a host comprising the compound of claim 1, or its pharmaceutically acceptable salt, in combination with one or more anti-hepatitis B virus agent.

### Claim 160 (depends on 159)

The composition of claim 159 wherein the anti-hepatitis B virus agent is a β-L-deoxyribonucleoside.

### Claim 161 (depends on 160)

The composition of claim 160 wherein the β-L-deoxyribonucleoside is selected from the group consisting of β-L-deoxyribothymidine (β-L-dT), β-L-deoxyribocytosine (β-L-dC), β-L-deoxyribouridine (β-L-dU), β-L-deoxyriboadenine (β-L-dA), β-L-deoxyriboguanine (β-L-dG) or β-L-deoxyribo-inosine (β-L-dI).

### Claim 162 (depends on 161)

The composition of claim 161 wherein the β-L-deoxyribonucleoside is β-L-deoxyribothymidine (β-L-dT).

### Claim 163

A pharmaceutical composition comprising a compound of the formula
40
or its pharmaceutically acceptable salt thereof, in combination with β-L-deoxyribothymidine.

### Claim 164

A pharmaceutical composition comprising a compound of the formula
41
or its pharmaceutically acceptable salt thereof, in combination with β-L-deoxyribothymidine.

### Claim 165 (depends on 1)

A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of the compound of claim 1, or its pharmaceutically acceptable salt thereof.

### Claim 166 (depends on 165)

The method of claim 165, wherein the compound is of the formula
42
or its pharmaceutically acceptable salt thereof.

### Claim 167 (depends on 165)

The method of claim 165, wherein the compound is of the formula
43
or its pharmaceutically acceptable salt thereof.

### Claim 168 (depends on 1)

A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a pharmaceutical composition comprising the compound of claim 1, or its pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 169 (depends on 1)

A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a compound of claim 1, or its pharmaceutically acceptable salt thereof, in combination or alternation with a therapeutic amount of one or more other anti-hepatitis B agent.

### Claim 170 (depends on 169)

The method of claim 169 wherein the anti-hepatitis B virus agent is a β-L-deoxyribonucleoside.

### Claim 171 (depends on 170)

The method of claim 170 wherein the β-L-deoxyribonucleoside is selected from the group consisting of β-L-deoxyribothymidine (β-L-dT), β-L-deoxyribocytosine (β-L-dC), β-L-deoxyribouridine (β-L-dU), β-L-deoxyriboadenine (β-L-dA), β-L-deoxyriboguanine (β-L-dG) or β-L-deoxyribo-inosine (β-L-dI).

### Claim 172 (depends on 171)

The method of claim 171 wherein the β-L-deoxyribonucleoside is β-L-deoxyribothymidine (β-L-dT).

### Claim 173

A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a pharmaceutical composition comprising a compound of the formula
44
or its pharmaceutically acceptable salt thereof, in combination or alternation with a therapeutic amount of β-L-deoxyribothymidine.

### Claim 174

A method for the treatment or prophylaxis of a hepatitis B virus infection in a host, comprising administering a therapeutic amount of a pharmaceutical composition comprising a compound of the formula
45
or its pharmaceutically acceptable salt thereof, in combination or alternation with a therapeutic amount of β-L-deoxyribothymidine.
